NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. (“Catalent” or the “Company”) CTLT. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.

The investigation concerns whether Catalent and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On August 29, 2022, Catalent announced that demand for its COVID-related products was facing significant headwinds.

As a result of this news, Catalent’s stock price fell $7.42 per share, or 7.4%, to close at $92.29 per share on August 29, 2022.

Then, on September 20, 2022, a Washington Post The report revealed that the release of Catalent-made COVID-19 vaccines had been delayed by regulators due to improper sterilization at one of Catalent’s key facilities.

As a result of this news, Catalent’s stock price fell $8.09 per share, or 9.3%, in the following two trading sessions to close at $79.06 per share on September 22, 2022.

Finally, on November 1, 2022, Catalent announced that its quarterly earnings had fallen to zero and lowered its financial guidance, indicating slowing demand. The company also announced that regulatory issues at key facilities negatively impacted its financial results.

As a result of this news, Catalent’s stock price fell $20.83 per share, or 31.7%, in the following two trading sessions to close at $44.90 per share on November 2, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he established…